Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
Author
Sherman, M.
Hindes, R. G.
Kaymakoglu, S.
Brett-Smith, H.
Vaughan, J.
Yurdaydin, C.
Sollano, J.
Hadziyannis, S.
Metadata
Show full item recordCollections
- Bildiri [64839]